Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.117
Sell
RSI(14)
36.611
Neutral
STOCH(KDJ)(9,3,3)
23.591
Buy
ATR(14)
0.374
Low Volatility
CCI(14)
-57.475
Neutral
Williams %R
75.291
Sell
TRIX(12,20)
-1.842
Sell
StochRSI(14)
100.000
Buy
Evaxion Biotech A/S
EVAX3.360USD
+0.450+15.46%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.06BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Evaxion Biotech A/S
Currency: USD Updated: 2026-02-06Key Insights
Evaxion Biotech A/S's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 179 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.33.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evaxion Biotech A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evaxion Biotech A/S Highlights
StrengthsRisks
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.34M.
Overvalued
The company’s latest PE is -0.21, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
12.333
Target Price
+323.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Evaxion Biotech A/S is 7.14, ranking 150 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 7.49M, representing a year-over-year increase of 148.33%, while its net profit experienced a year-over-year increase of 338.66%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.93
Operational Efficiency
4.00
Growth Potential
6.87
Shareholder Returns
6.91
Evaxion Biotech A/S's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Evaxion Biotech A/S is 6.49, ranking 268 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.21, which is -41.21% below the recent high of -0.12 and -10271.42% above the recent low of -21.59.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 179/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Evaxion Biotech A/S is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 16.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
12.333
Target Price
+294.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Evaxion Biotech A/S
EVAX
3
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Evaxion Biotech A/S is 4.49, ranking 346 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.86 and the support level at 2.37, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.138
Buy
MA10
3.373
Sell
MA20
4.029
Sell
MA50
4.866
Sell
MA100
5.191
Sell
MA200
3.830
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Evaxion Biotech A/S is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.61%, representing a quarter-over-quarter decrease of 8.33%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Evaxion Biotech A/S. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.30
VaR
+9.23%
240-Day Maximum Drawdown
+73.57%
240-Day Volatility
+114.29%
Return
Best Daily Return
60 days
+19.62%
120 days
+40.43%
5 years
+113.43%
Worst Daily Return
60 days
-18.26%
120 days
-29.27%
5 years
-45.36%
Sharpe Ratio
60 days
-2.95
120 days
+0.62
5 years
-0.18
Risk Assessment
Maximum Drawdown
240 days
+73.57%
3 years
+98.50%
5 years
+99.79%
Return-to-Drawdown Ratio
240 days
+0.51
3 years
-0.32
5 years
-0.20
Skewness
240 days
+1.24
3 years
+3.54
5 years
+4.07
Volatility
Realised Volatility
240 days
+114.29%
5 years
+157.32%
Standardised True Range
240 days
+11.11%
5 years
+277.28%
Downside Risk-Adjusted Return
120 days
+109.87%
240 days
+109.87%
Maximum Daily Upside Volatility
60 days
+77.38%
Maximum Daily Downside Volatility
60 days
+68.91%
Liquidity
Average Turnover Rate
60 days
+0.76%
120 days
+0.68%
5 years
--
Turnover Deviation
20 days
-96.78%
60 days
-95.87%
120 days
-96.33%
Peer Comparison
Biotechnology & Medical Research
Evaxion Biotech A/S
EVAX
5.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
